TW200815363A - KV1.5 potassium channel inhibitors - Google Patents

KV1.5 potassium channel inhibitors

Info

Publication number
TW200815363A
TW200815363A TW096122064A TW96122064A TW200815363A TW 200815363 A TW200815363 A TW 200815363A TW 096122064 A TW096122064 A TW 096122064A TW 96122064 A TW96122064 A TW 96122064A TW 200815363 A TW200815363 A TW 200815363A
Authority
TW
Taiwan
Prior art keywords
potassium channel
channel inhibitors
present
relates
imidazolidinones
Prior art date
Application number
TW096122064A
Other languages
English (en)
Chinese (zh)
Inventor
John Michael Janusz
Stephen Joseph Hodson
Ronald Eugene White
Gregory Kent Bosch
Benjamin E Blass
Christopher M Jackson
Neil T Fairweather
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200815363A publication Critical patent/TW200815363A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW096122064A 2006-06-20 2007-06-20 KV1.5 potassium channel inhibitors TW200815363A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81509106P 2006-06-20 2006-06-20
US11/765,359 US7504517B2 (en) 2006-06-20 2007-06-19 Kv1.5 potassium channel inhibitors

Publications (1)

Publication Number Publication Date
TW200815363A true TW200815363A (en) 2008-04-01

Family

ID=38582320

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096122064A TW200815363A (en) 2006-06-20 2007-06-20 KV1.5 potassium channel inhibitors

Country Status (20)

Country Link
US (2) US7504517B2 (enExample)
EP (1) EP2035392A1 (enExample)
JP (1) JP2009541343A (enExample)
KR (1) KR20090021223A (enExample)
CN (1) CN101573341A (enExample)
AR (1) AR061523A1 (enExample)
AU (1) AU2007260985A1 (enExample)
BR (1) BRPI0713320A2 (enExample)
CA (1) CA2655574A1 (enExample)
CL (1) CL2007001794A1 (enExample)
CO (1) CO6150173A2 (enExample)
CR (1) CR10527A (enExample)
EC (1) ECSP088994A (enExample)
MX (1) MX2008016399A (enExample)
NO (1) NO20085252L (enExample)
PE (1) PE20080942A1 (enExample)
RU (1) RU2008150465A (enExample)
TW (1) TW200815363A (enExample)
WO (1) WO2007149874A1 (enExample)
ZA (1) ZA200810763B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007001794A1 (es) * 2006-06-20 2008-01-18 Wyeth Corp Compuestos derivados de 2-imidazolidinona, inhibidores del canal de potasio kv1.5; composicion farmaceutica que los comprende; y su uso para tratar o prevenir arritmias cardiacas. tromboembolia,apoplejia,insuficiencia cardiaca.
RU2373934C1 (ru) * 2008-03-19 2009-11-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств
CN101544580B (zh) * 2009-04-28 2019-03-15 大连凯飞精细化工有限公司 R-alpha-氨基-4-甲氧基苯乙酰胺的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099009A (en) * 1977-04-11 1978-07-04 Morton-Norwick Products, Inc. 1-(4-chlorophenyl)-3-(1-ureido)-2-imidazolidinone
SK94393A3 (en) 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
DE4332168A1 (de) 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CA2243121A1 (en) 1996-01-26 1997-07-31 Francesco Gerald Salituro Aspartyl protease inhibitors
AU716153B2 (en) 1996-04-03 2000-02-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US7129359B2 (en) * 2002-07-09 2006-10-31 National Health Research Institutes Imidazolidinone compounds
BR0214437A (pt) 2001-11-30 2004-10-13 Lilly Co Eli Composto, composição farmacêutica, métodos de modular um receptor ativado por proliferador de peroxissoma, de tratar e de prevenir a diabete melito, e de tratar a sìndrome x, e doenças cardiovasculares em um mamìfero, e, uso de um composto
WO2003057214A1 (en) 2001-12-28 2003-07-17 Somatocor Pharmaceuticals, Inc. Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
WO2004046137A1 (en) 2002-11-21 2004-06-03 Vicore Pharma Ab New tricyclic angiotensin ii agonists
JP2004262903A (ja) 2003-03-04 2004-09-24 Japan Science & Technology Agency アジリジン類の製造方法
US7259174B2 (en) * 2004-05-25 2007-08-21 National Health Research Institutes Imidazolidinone compounds
AR050858A1 (es) 2004-09-07 2006-11-29 Glaxo Group Ltd Compuesto de heteroaril-nitrilo sustituido, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para la preparacion del mismo
KR100677149B1 (ko) * 2004-11-12 2007-02-02 삼성전자주식회사 잉크 조성물
CL2007001794A1 (es) * 2006-06-20 2008-01-18 Wyeth Corp Compuestos derivados de 2-imidazolidinona, inhibidores del canal de potasio kv1.5; composicion farmaceutica que los comprende; y su uso para tratar o prevenir arritmias cardiacas. tromboembolia,apoplejia,insuficiencia cardiaca.

Also Published As

Publication number Publication date
CR10527A (es) 2009-02-19
WO2007149874A1 (en) 2007-12-27
WO2007149874A8 (en) 2008-03-20
BRPI0713320A2 (pt) 2012-02-07
ECSP088994A (es) 2009-01-30
US7803827B2 (en) 2010-09-28
RU2008150465A (ru) 2010-07-27
EP2035392A1 (en) 2009-03-18
NO20085252L (no) 2009-01-13
MX2008016399A (es) 2009-02-03
CN101573341A (zh) 2009-11-04
US20090069342A1 (en) 2009-03-12
CA2655574A1 (en) 2007-12-27
CO6150173A2 (es) 2010-04-20
US7504517B2 (en) 2009-03-17
AR061523A1 (es) 2008-09-03
AU2007260985A1 (en) 2007-12-27
JP2009541343A (ja) 2009-11-26
US20070299120A1 (en) 2007-12-27
CL2007001794A1 (es) 2008-01-18
KR20090021223A (ko) 2009-02-27
ZA200810763B (en) 2009-09-30
PE20080942A1 (es) 2008-09-03

Similar Documents

Publication Publication Date Title
ZA200802848B (en) Potassium channel inhibitors
WO2005030791A3 (en) Isoquinolinone potassium channel inhibitors
MX2007006178A (es) Fenoles substituidos como agentes activos que inhiben la produccion del factor de crecimiento endotelial vascular.
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
WO2005030129A3 (en) Quinoline potassium channel inhibitors
MXPA05013553A (es) Pirrolodihidroisoquinolinas como inhibidores de pde10.
WO2007092622A3 (en) Compositions and methods for treating bone
IL190632A0 (en) Biphenyl derivatives and pharmaceutical compositions containing the same
WO2005046578A3 (en) Isoquinolinone potassium channel inhibitors
UA103181C2 (ru) Соединения, которые ингибируют дипептидилпептидазу-iv и фармацевтическая композиция, которая содержит их как активный агент
TNSN07222A1 (en) Nematicidal compositions
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2005030130A3 (en) Isoquinoline potassium channel inhibitors
WO2007026251A3 (en) Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
TW200800967A (en) Benzimidazole thiophene compounds
WO2010021934A3 (en) Azaindole inhibitors of iap
EP2129672A4 (en) ESTER AND CARBAMATE AZAADAMANTANE DERIVATIVES AND METHODS OF USE
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
WO2007149873A3 (en) Kv1.5 potassium channel inhibitors
TW200716088A (en) Formulations and methods for treating amyloidosis
WO2005030792A3 (en) Quinoline potassium channel inhibitors
TW200815363A (en) KV1.5 potassium channel inhibitors
WO2010011684A3 (en) Prodrug and fluoregenic compositions and methods for using the same